茶色素及维生素E对冠心病患者血浆vWF、0xLDL水平的影响

目的：本文观察了65例冠心病（CHD）患者口服茶色素及维生素E（VitE)后血浆血管性假血友病因子（vWF)和氧化型低密度脂蛋白（oxLDL)的改变，并探讨其改变的临床意义。方法：65例确诊为冠心病患者随机给予口服茶色素（375mg/d)、VitE(100mg/d)和安慰剂（粒／天），时间8周。采用酶标法测定血浆vWF和oxLDL。结果：服药前3组CHD患者血浆vWF和oxLDL水平高于正常对照组（P＜0．01）；与服药前相比，服药4周后，茶色素组、VitE组病人的血浆vWF和oxLDL水平下降（P＜0．05）；服药8周时，血浆oxLDL水平在茶色素组和VitE组患者均可见进一步下降（P＜0．01），而血浆vWF水平则有所不同，茶色素组进一步下降（P＜0．01），VitE组病人未见进一步下降，与服药4周时相当（P＜0．05）；服药前茶色素组、VitE组及安慰剂组3组患者的血浆vWF和oxLDL水平无统计学差异（P＞0．05）。结论：CHD患者存在内皮功能不全和动脉血栓形成倾向，茶色素和VitE具有改善内皮功能不全、抑制动脉血栓形成和抑制LDL氧化作用，因而对阻止动脉粥样硬化（AS）的进一步发展可能得到有益作用。

Effects of Rubigin and VitE on Plasma vWF and ox - LDL levels in Patients with Coronary Heart Disease

Objective: To investigate the changes of plasma vWF and oxLDL levels in 65 patients with coronary heart disease (CHD) after administration of rubigin and VitE and discussed its clinical significance. Methods: 65 patients with CHD randomly took Rubigin (375mg/d), VitE(100mg/d) or placebo (pellet/d) for 8 weeks. Plasma vWF and oxLDL were measured with enzyme linked immunosorbant assay(ELISA). Results: The basal values of plasma vWF and oxLDL in patients with CHD were higher than that in control group(P<0.01). Compared with baseline, Patients on rubigin showed a statistically decrease in plasma oxLDL and vWF 4 - week after administration (P<0.05), followed by a remarkable reduction at 8 weeks(F <0.01). Plasma oxLDL in VitE group decreased significantlyat 4 weeks(P<0.05) and reduced more remarkably 8 week after administration (P<0.01). Patients on VitE showed a statistically decrease in plasma vWF at 4 and 8 weeks(P<0. 05). Conclusion: Rubigin and VitE could improve endothelial dysfunction , inhibit artery thrombosis and the oxidation of LDL in patients with CHD and play a beneficial role in prohibiting the progression of CHD.